Charles River Laboratories Total Liabilities 2010-2025 | CRL

Charles River Laboratories total liabilities for the quarter ending March 31, 2025 were $4.382B, a 2.76% decline year-over-year.

  • Charles River Laboratories total liabilities for 2024 were $4.061B, a 11.57% decline from 2023.
  • Charles River Laboratories total liabilities for 2023 were $4.593B, a 0.63% decline from 2022.
  • Charles River Laboratories total liabilities for 2022 were $4.622B, a 3.04% increase from 2021.

Charles River Laboratories Total Liabilities 2010-2025 | CRL

  • Charles River Laboratories total liabilities for 2024 were $4.061B, a 11.57% decline from 2023.
  • Charles River Laboratories total liabilities for 2023 were $4.593B, a 0.63% decline from 2022.
  • Charles River Laboratories total liabilities for 2022 were $4.622B, a 3.04% increase from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$146.6B
CVS Health (CVS)$81.9B
Elevance Health (ELV)$77B
Cencora (COR)$57.2B
DiDi Global (DIDIY)$24.2B
Natera (NTRA)$21.9B
Labcorp Holdings (LH)$20.9B
BioMerieux (BMXMF)$16.9B
EUROFINS SCIENT (ERFSF)$13.7B
CochLear (CHEOY)$12.8B
Solventum (SOLV)$12.8B
ICON (ICLR)$12.2B
Revvity (RVTY)$12B
Viatris (VTRS)$10.7B
Medpace Holdings (MEDP)$9.3B
Avantor (AVTR)$9.3B
Sonic Healthcare (SKHHY)$8.9B
HealthEquity (HQY)$8.2B
Caris Life Sciences,�Inc (CAI)$6.7B
Amplifon S.p.A (AMFPF)$5.4B
Bausch + Lomb (BLCO)$4.9B
BrightSpring Health Services (BTSG)$3.6B
Sotera Health (SHC)$3.3B
Surgery Partners (SGRY)$2.8B
Alignment Healthcare (ALHC)$2.6B
Organon (OGN)$2.6B
Concentras Parent (CON)$2.6B
GeneDx Holdings (WGS)$2.4B
Ardent Health (ARDT)$2B
Progyny (PGNY)$2B